Lanoconazole

SKU: orb1940881

Description

Lanoconazole is a potent and orally active imidazole antifungal agent, shows a broad spectrum of activity against fungi in vitro and in vivo. Lanoconazole interferes with ergosterol biosynthesis by inhibiting sterol 14-alpha demethylase and blocking fungal membrane ergosterol biosynthesis. Lanoconazole can be used for the investigation of dermatophytosis and onychomycosis. Lanoconazole (treatment for ear; 0.3%-3%; 6 days) dose‐dependently suppresses TPA-induced irritant dermatitis, suppresses the production of neutrophil chemotactic factors such as keratinocyte‐derived chemokine and macrophage inflammatory protein‐2, and inhibited neutrophil infiltration to the inflammation site. Lanoconazole (oral administration; 3, 10 or 30 mg/kg; once a day; 3 weeks) significantly inhibits C. neoformans compared with the saline control in normal mice. In addtion, it significantly reduces the growth of C. neoformans in the lungs and brains of MAIDS mice.

Research Area

Pharmacology & Drug Discovery

Key Properties

• CAS Number: 101530-10-3
• MW: 319.83
• Purity: >98% (HPLC)
• Formula: C₁₄H₁₀ClN₃S₂
• SMILES: N#C/C(N1C=CN=C1)=C2SC(C(C=CC=C3)=C3Cl)CS\2.[(E)]
• Target: Fungal
• Solubility: DMSO : 100 mg/mL (312.67 mM; Need ultrasonic)

Bioactivity

• In Vivo:
  Animal model: BALB/c mice. Dosage: 0.3%-3% dosage. Administration: Treatment for ear. Result: Exhibited an inhibition effect of LCZ on ear swelling induced by topical application of TPA in mice. Animal model: Four week old C57BL/6 mice infected intraperitoneally with LP-BM5 murine leukaemia virus. Dosage: 3, 10 or 30 mg/kg. Administration: Oral adminstration. Result: Inhibited C. neoformans growth in both normal and C. neoformans-induced encephalitis MAIDS mice.

Storage & Handling

• Storage: Storage temperature: -20°C. Stability: ≥ 2 years
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Quick Database Links

Gene Symbol

Fungal